Unlock instant, AI-driven research and patent intelligence for your innovation.

Engineered cardiomyocytes and uses thereof

A cardiomyocyte, engineering technology, applied in the fields of cell biology, pluripotent stem cells and cell differentiation, can solve problems such as unclear gene regulatory network interactions

Inactive Publication Date: 2019-04-16
THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADS
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is unclear what specific disruption of gene regulatory network interactions contributes to human disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Engineered cardiomyocytes and uses thereof
  • Engineered cardiomyocytes and uses thereof
  • Engineered cardiomyocytes and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0241] Example 1: Generation of patient-specific iPS cells and functionally engineered cardiomyocytes

[0242] A heterozygous c.886G>A mutation in human GATA4 is associated with 100% permeable atrial or ventricular septal defect, AVSD, and pulmonary stenosis (PS) (Figures 1 and 2) (Garg et al., 2003). Mutant GATA4 translates into a G296S missense substitution flanking the zinc finger domain, a region involved in DNA binding and protein-protein interactions (Fig. 1, lower panel). identified several GATA4 G296S patients who developed tardive cardiomyopathy in their juvenile years. It is characterized by reduced left ventricular systolic function and abnormal right ventricular echocardiographic findings with deep trabeculation and papillary muscle thickening in the left ventricle (Figure 3). Profound trabecular formation is typical of a condition known as noncompaction, which is thought to reflect failure of ventricular myocyte maturation (Hutchins and Schaefer, 2012). This cli...

Embodiment 2

[0245] Example 2: Impaired contractility, calcium regulation, metabolic activity of GATA4 mutant engineered cardiomyocytes

[0246] Production of cTnT with wild-type (WT), G296S, and CRISPR-corrected isogenic IPS cells + D32-cardiomyocytes (Fig. 19), although the mutant line showed a slight delay in the onset of spontaneous contraction (Fig. S3A-B). To more precisely model the contractile properties of mature cardiomyocytes, a physiological micropatterning platform for single iPS-derived cardiomyocytes was designed (Fig. 20) (Ribeiro et al., 2015). Compared with 70% of wild-type cardiomyocytes, only 50% of patterned G296S cardiomyocytes accurately responded to electrical pacing at 1 Hz; although wild-type cells did not respond to pacing at frequencies above 1 Hz, 20% of G296S cardiomyocytes were able to beat at this faster rate (Figure 21). G296S cardiomyocytes also had significantly reduced contractile force production / cell motility and shortened contraction times (Figures...

Embodiment 3

[0248] Example 3: Attenuation of the Cardiac Gene Program in Mutant CPCs and Cardiomyocytes

[0249]RNA-seq was performed on isogenic iPS cells at day 7 during cardiac differentiation into CPCs, contracting cardiomyocytes before (D15) and after lactate purification (D32) ( FIG. 28 ). The LASSO regression algorithm (Roost et al., 2015) accurately predicted that our iWT cardiomyocyte data represented the cardiac transcriptome (0.6-1) rather than other human tissues, whereas the G296S transcriptome from CPC, D15-cardiomyocytes and D32-cardiomyocytes Consistently low cardiac score (<0.6) (Figure 29). During at least one of the 3 time points, 2228 genes were differentially expressed in G296S cells with significant dynamic changes from CPC to mature cardiomyocytes (Fig. 30,31). There were 38 genes involved in the Wnt-PCP pathway, or vasculature, endocardium, cardiac development and cardiac progenitor cell differentiation that were consistently downregulated or upregulated (Figures ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides the development of engineered cardiomyocytes having mutations in transcription factor involved in vivo with cardiac development and / or function. These cell populationscomprise mutations that are associated with deleterious effects in vivo in mammals. The mutations of the engineered cardiomyocytes of the disclosure thus are rationally designed based on demonstratedphysiological effects in mammals, e.g., mice or humans.

Description

field of invention [0001] The present invention relates generally to the fields of cell biology, pluripotent stem cells and cell differentiation. The invention discloses a neural precursor cell population and its therapeutic use. [0002] Federally funded research and development [0003] This invention was made with Government support under Grant No. HL089707 awarded by the National Institutes of Health. The government has certain rights in this invention. [0004] cross reference [0005] This application claims the benefit of US Provisional Patent Application No. 62 / 354937, filed June 27, 2016, which is incorporated herein by reference in its entirety. Background of the invention [0006] In the following discussion certain articles and methods are described for background and introductory purposes. Nothing contained herein should be construed as an "admission" of prior art. Applicant expressly reserves the right, where appropriate, to demonstrate that the articles ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/34C12N5/0735C12N5/16A61P9/00
CPCA61K35/34C12N5/0657C12N2506/45C12N2510/00A61P9/00C12N2501/999C12N2503/00G01N33/5044
Inventor D.斯里瓦斯塔瓦Y-S.洪
Owner THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADS